Skip to main content
SpringerLink
Log in

Difficultés alimentaires liées à la chimiothérapie

Chemotherapy-induced oral food intake impairment

  • Synthèse / Review Article
  • Published:
Oncologie

Abstract

Nausea-vomiting, taste and olfactory disorders and mucositis induced by cancer treatment have a significant impact on a patient’s everyday life. It has been shown that these secondary effects are influenced by several risk factors including both treatment and patient characteristics. Impairment of daily life, particularly in oral food intake, is associated with a large spectrum of chemosensory dysfunctions that impact on patient quality of life. To date, it is well established that these symptoms are often underestimated and that their nutritional and psychosocial impacts are not yet sufficiently evaluated. Better knowledge of these chemotherapy-induced side effects and their related chemosensory dysfunction is warranted in order to provide evidence-based clinical preventive and therapeutic guidelines.

Résumé

Les difficultés alimentaires secondaires à la chimiothérapie sont principalement la conséquence des toxicités digestives chimio-induites. Ainsi, les effets secondaires tels que les nausées-vomissements, les mucites, mais également les troubles du goût et de l’odorat ou bien encore l’asthénie peuvent induire des difficultés alimentaires dont l’incidence et l’intensité sont dépendantes des caractéristiques du traitement carcinologique, mais aussi de celles du patient. Les difficultés alimentaires se caractérisent ainsi par un large spectre de symptômes qui peuvent avoir un impact sur la qualité de vie des patients. À l’heure actuelle, ces différents troubles restent encore trop souvent sous-estimés par les cliniciens, et leurs conséquences tant nutritionnelles que psychologiques, sociales et culturelles ne sont pas clairement évaluées. Une meilleure connaissance des effets secondaires liés à la chimiothérapie et de leurs symptômes associés est donc indispensable, car elle peut permettre d’instaurer une prise en charge préventive et thérapeutique adaptée.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Références

  1. Bensinger W, Shubert M, Ang K, et al. (2008) NCCN Task force report: prevention and management of mucositis in cancer care. JNCCN 6(Suppl1): S1–S21

    PubMed  CAS  Google Scholar 

  2. Bernhardson BM, Tishelman C, Rutqvist LE (2007) Chemosensory changes experienced by patients undergoing cancer chemotherapy: a qualitative interview study. J Pain Symptom Manage 34: 403–412

    Article  PubMed  Google Scholar 

  3. Bernhardson BM, Tishelman C, Rutqvist LE (2008) Self-reported taste and smell changes during cancer chemotherapy. Support Care Cancer 16: 275–283

    Article  PubMed  Google Scholar 

  4. Bernstein IL (1978) Learned taste aversions in children receiving chemotherapy. Science 200: 1302–1303

    Article  PubMed  CAS  Google Scholar 

  5. Berteretche MV, Dalix AM, d’Ornano AM, et al. (2004) Decreased taste sensitivity in cancer patients under chemotherapy. Support Care Cancer 12: 571–576

    Article  PubMed  CAS  Google Scholar 

  6. Blijlevens N, Schwenkglenks M, Bacon P, et al. (2008) Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy: European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 26: 1519–1525

    Article  PubMed  CAS  Google Scholar 

  7. Bloechl-Daum B, Deuson R, Mavros P, et al. (2006) Delayed nausea and vomiting continue to reduce patient’s quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24: 4472–4478

    Article  PubMed  CAS  Google Scholar 

  8. Brisbois TD, Hutton JL, Baracos VE, Wismer WV (2006) Taste and smell abnormalities as an independent cause of failure of food intake in patients with advanced cancer-an argument for the application of sensory science. J Palliat Care 22: 111–114

    PubMed  Google Scholar 

  9. Cancer Care Ontario Practice Guidelines Initiative: use of 5-HT3 antagonists in patients receiving moderately or highly emetogenic chemotherapy (2000) Practice guideline report 12–3, 1/2003 update. http//www.cancercare.on.ca/pdf/pebc12_3f.pdf

  10. Comeau TB, Epstein JB, Migas C (2001) Taste and smell dysfunction in patients receiving chemotherapy: a review of current knowledge. Support Care Cancer 9: 575–580

    Article  PubMed  CAS  Google Scholar 

  11. D’Acquisto RW, Tyson LB, Gralla RJ, et al. (1987) The influence of chronic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 5: 257 (Abstr 1006)

    Google Scholar 

  12. De Boer-Dennert M, de Wit R, Schmitz P, et al. (1997) Patients perceptions of the side effects of chemotherapy: the influence of 5-HT3 antagonists. Br J Cancer 76: 1055–10561

    PubMed  Google Scholar 

  13. De Wit R, Herrstedt J, Rapoport B, et al. (2003) Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 21: 4105–4111

    Article  PubMed  CAS  Google Scholar 

  14. Duncan M, Grant G (2003) Review article: oral and intestinal mucositis: causes and possible treatments. Aliment Pharmacol Ther 18: 853–874

    Article  PubMed  CAS  Google Scholar 

  15. Enquêtes sur les difficultés alimentaires liées à une chimiothérapie (2006) Rapport final juin Institut national du cancer. http://www.e-cancer.fr/v1/fichiers/public/enquete_difficultees_alimentaires_chimiotherapie_050906.pdf

  16. Greling O, Eicher H (2005) Should 5-HT3 receptor antagonists be administered beyond 24 hours following chemotherapy to prevent delayed emesis? Systematic reevaluation of clinical evidence and drug cost implications. J Clin Oncol 23: 1289–1294

    Article  CAS  Google Scholar 

  17. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358: 2482–2494

    Article  PubMed  CAS  Google Scholar 

  18. Hesketh PJ, Grunberg SM, Gralla RJ, et al. (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomised, double blind, placebo-controlled trial in patients receiving high-dose cisplatin: the Aprepitant Protocol 052 Study Group. J Clin Oncol 21: 4112–4119

    Article  PubMed  CAS  Google Scholar 

  19. Hesketh PJ, Kris MG, Grunberg SM, et al. (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15: 103–109

    PubMed  CAS  Google Scholar 

  20. Hutton JL, Baracos VE, Wismer WV (2007) Chemosensory dysfunction is a primary factor in the evolution of declining nutritional status and quality of life in patients with advanced cancer. J Pain Symptom Manage 33: 156–165

    Article  PubMed  Google Scholar 

  21. Jakubowicz C (2005) Troubles du goût et de l’alimentation chez les malades du cancer traités par chimiothérapie. Institut national du cancer https://www.e-cancer.fr/v1/fichiers/public/troubles_gout_alimentation_schum.doc

  22. Jakubowicz C (2006) Chemotherapy and the pleasure of eating. The point of view of the human sciences. Oncology 170–174

  23. Jordan K, Kasper C, Schmoll HJ (2005) Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer 41: 199–205

    Article  PubMed  CAS  Google Scholar 

  24. Keefe D, Shubert M, Elting L, et al. (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109: 820–831

    Article  PubMed  CAS  Google Scholar 

  25. Kettaneh A, Fain O, Stirnemann J, Thomas M (2002) Taste disorders. Rev Med Int 23: 622–631

    Article  CAS  Google Scholar 

  26. Kris MG, Hesketh PJ, Somerfield MR, et al. (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24: 2932–2947

    Article  PubMed  CAS  Google Scholar 

  27. Lipkin M (1965) Cell replication in the gastro-intestinal tract of man. Gastroenterology 48: 616–662

    PubMed  CAS  Google Scholar 

  28. Lipkin M, Sherlock P, Bell B (1965) Cell proliferation kinetics in the gastro-intestinal tract of man. II Cell renewal in the stomach ileum, colon, rectum. Gastroenterology 45: 721–772

    Google Scholar 

  29. Mitchell E (2006) Gastro-intestinal toxicity of chemotherapeutic agents. Semin Oncol 33: 106–120

    Article  PubMed  CAS  Google Scholar 

  30. Naeim A, Dry S, Lorenz K, et al. (2008) Evidence-based recommendations for cancer nausea and vomiting. J Clin Oncol 26: 3903–3910

    Article  PubMed  Google Scholar 

  31. Raber-Durlacher J, Weijl N, Abus Saris M, et al. (2000) Oral mucositis in patients treated with chemotherapy for solids tumors: a retrospective analysis of 150 cases. Support Care Cancer 8: 366–371

    Article  PubMed  CAS  Google Scholar 

  32. Rosen L, Abdi E, Davis I, et al. (2006) Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 24: 5194–5200

    Article  PubMed  CAS  Google Scholar 

  33. Schwartz MD, Jacobsen PB, Bovbjerg DH (1996) Role of nausea in the development of aversions to a beverage paired with chemotherapy treatment in cancer patients. Physiol Behav 59: 659–663

    Article  PubMed  CAS  Google Scholar 

  34. Sonis S (1998) Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34: 39–43

    Article  PubMed  CAS  Google Scholar 

  35. Sonis S, Oster G, Fucks H, et al. (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19: 2201–2205

    PubMed  CAS  Google Scholar 

  36. Strasser F, Demmer R, Böhme C, et al. (2008) Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double blind study. Oncologist 13: 337–346

    Article  PubMed  CAS  Google Scholar 

  37. Wickham R, Rehwaldt M, Kefer C, et al. (1999) Taste changes experienced by patients receiving chemotherapy. Oncol Nurs Forum 26: 697–706

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unité d’oncologie urodigestive, CHU Charles-Nicolle, 1, rue de Germont, F-76031, Rouen, France

    F. Di Fiore & O. Rigal

  2. Département d’oncologie médicale et service des soins de support, CRLCC Henri-Becquerel, 1, rue d’Amiens, F-76038, Rouen, France

    F. Di Fiore & O. Rigal

Authors
  1. F. Di Fiore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Rigal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to F. Di Fiore or O. Rigal.

About this article

Cite this article

Di Fiore, F., Rigal, O. Difficultés alimentaires liées à la chimiothérapie. Oncologie 11, 204–210 (2009). https://doi.org/10.1007/s10269-009-1051-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-009-1051-3

Keywords

Mots clés

Search

Navigation